Proven Safe & Effective.

iLink cross-linking is a minimally-invasive treatment proven to be safe and effective in slowing or halting the progression of keratoconus to preserve vision.

FDA-Approved.

iLink is the only FDA-approved corneal cross-linking procedure and has been approved in the United States since April 2016.

Validated in Clinical Trials.

Unlike iLink, unapproved drugs and devices have not been validated and their manufacturing process has not been evaluated.

Widely Covered by Insurance.

iLink cross-linking is widely covered by insurance and is the ONLY cross-linking procedure eligible for reimbursement in the U.S.

You may want to consider seeking a second opinion if:

  • Your doctor recommends a cross-linking procedure that has not been FDA-approved.
  • Your doctor asks you to pay cash and submit to insurance on your own.
  • Your doctor suggests that you pay for treatment as part of their own trial. (Clinical trials for FDA-approval are typically free to patients).
  • Your doctor tells you that their cross-linking procedure is not covered by insurance.

Have you asked your doctor if the cross-linking they perform is FDA-approved and covered by insurance?

Visit our physician locator to view the list of doctors performing iLink FDA-approved cross-linking in the U.S.

Key Differences Between iLink and Non-FDA Approved Procedures:

How can you make sure you are receiving the FDA-approved procedure?

Check our physician locator to make sure your doctor is listed! This list includes the U.S. physicians performing iLink FDA-approved cross-linking.

Why does FDA-approved matter?

  • Drug manufacturers spend years in pre-clinical development and three phases of clinical trials to ensure the safety and efficacy of their products and procedures.
  • Upon submission, the FDA carefully vets new candidates and drugs via panels of experts and specialists.
  • Approval is granted based on credible, statistically significant research trials demonstrating safety and efficacy with strict post-marketing tracking, marketing and quality monitoring requirements.
  • For unapproved drugs and devices, the FDA has not determined that they are safe and effective; they may not be approved for use outside of clinical trials authorized by the FDA and they may not be legally marketed to patients.
  • While manufacturers of FDA-approved drugs and devices are required to report adverse experiences to the FDA, there is no equivalent reporting required for unapproved products, which may present a risk to public safety.

Efficacy of the FDA-Approved iLink Cross-Linking Procedure vs Unapproved Cross-Linking Procedures

  • Only iLink has been proven safe and effective by the FDA
  • Clinical trials demonstrated that the iLink cross-linking procedure is effective in slowing or halting the progression of keratoconus. In the study that led to the FDA-approval of iLink, patients who did not undergo cross-linking continued to progress, while patients who underwent iLink cross-linking did not progress1, 2.
  • The goal of the iLink cross-linking procedure is slow or halt the progression of keratoconus to preserve vision.

What’s more important than your sight?

Don’t risk your vision on a product or procedure that does not have proven safety and efficacy. If your keratoconus is not effectively treated and continues to progress, you may lose vision that cannot be recovered.

Have you asked your doctor if the cross-linking treatment they perform is FDA-approved and covered by insurance?

Visit our physician locator to view the list of doctors performing iLink FDA-approved cross-linking in the U.S.

MA-02113A

1. Hersh PS, Stulting RD, Muller D, et al; U.S. Crosslinking Study Group. S. Multicenter Clinical Trial of Corneal Collagen Crosslinking for Treatment of Corneal Ectasia after Refractive Surgery. Ophthalmology 2017;124(9):1475-84.

2. Hersh PS, Stulting RD, Muller D, et al; U.S. Crosslinking Study Group. United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment. Ophthalmology 2017; 124(9):1259-70.

3. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016.

© 2021 Glaukos Corporation. iLink ™ is a trademark of Glaukos Corporation. Photrexa ® and KXL® are registered trademarks of Avedro, Inc, a Glaukos Company.